Discov Med. 2007 Feb;7(37):39-45.

Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.

Source

Oncology Research Centre, Prince of Wales Hospital, Level 2, Clinical Sciences Building, Barker St., Randwick, NSW 2031, Australia.

Abstract

Late stage hormone refractory prostate cancer (HRPC) is presently incurable. Novel alternatives such as cytoreductive Gene Directed Enzyme Prodrug Therapy (GDEPT) offer great hope: The potential for in situ amplification of cytotoxicity due to GDEPT-associated "bystander effects" has special appeal for patients with prostate cancer, the prostate being dispensable. In this overview, recent developments in various GDEPT systems for treating prostate cancer are described. Research related to the enhancement of in situ GDEPT delivery and prostate cancer-targeting of viral vectors, is reviewed. The scope and progress of synergies between GDEPT and other treatment modalities, traditional and alternate, are discussed.

PMID:: 17343804; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Discovery Medicine

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Novel gene-directed enzyme prodrug therapies against prostate cancer. [Expert Opin Investig Drugs. 2006]
Review Novel gene-directed enzyme prodrug therapies against prostate cancer.
Russell PJ, Khatri A. Expert Opin Investig Drugs. 2006 Aug; 15(8):947-61.
Review Prodrug cancer gene therapy. [Cancer Lett. 2008]
Review Prodrug cancer gene therapy.
Altaner C. Cancer Lett. 2008 Nov 8; 270(2):191-201. Epub 2008 May 27.
Review Viral vectors for gene-directed enzyme prodrug therapy. [Curr Gene Ther. 2006]
Review Viral vectors for gene-directed enzyme prodrug therapy.
Schepelmann S, Springer CJ. Curr Gene Ther. 2006 Dec; 6(6):647-70.
Review Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer? [Anticancer Agents Med Chem. 2008]
Review Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?
Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Nishiyama Y, Kikkawa F. Anticancer Agents Med Chem. 2008 Feb; 8(2):232-9.
Review Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. [Curr Opin Mol Ther. 2009]
Review Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.
Both GW. Curr Opin Mol Ther. 2009 Aug; 11(4):421-32.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggress...
Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer.
Discov Med. 2007 Feb ;7(37):39-45.

PubMed
Adverse childhood experiences and mental health in young adults: a longitudinal ...
Adverse childhood experiences and mental health in young adults: a longitudinal survey.
BMC Public Health. 2007 Mar 7 ;7:30.

PubMed
Index-of-refraction-dependent subcellular light scattering observed with organel...
Index-of-refraction-dependent subcellular light scattering observed with organelle-specific dyes.
J Biomed Opt. 2007 Jan-Feb ;12(1):014010.

PubMed
Evaluating the postmarketing experience of risperidone use during pregnancy: pre...
Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
Drug Saf. 2007 ;30(3):247-64.

PubMed
Cancer cachexia and immunomodulation.
Cancer cachexia and immunomodulation.
J BUON. 2005 Apr-Jun ;10(2):181-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: